Factor Telaprevir (n=46) Boceprevir (n=26) PEG/RBV (n=72) P
HCV Mode of Transmission, n (%)        
IVDU 13 (33.3) 8 (40.0) 25 (54.3) 0.14
Blood transfusion 13 (33.3) 9 (45.0) 22 (47.8) 0.38
Tattoo 5 (12.8) 3 (15.0) 9 (19.6) 0.69
Cocaine 2 (5.1) 4 (20.0) 7 (15.2) 0.19
Health-care associated 1 (2.6) 1 (5.0) 4 (8.7) 0.47
Vertical Transmission 3 (7.7) 1 (5.0) 0 (0.0) 0.17
Fibrosis stage       0.15
 0 3 (7.3) 6 (24.0) 8 (11.4)  
 1 5 (12.2) 4 (16.0) 12 (17.1)  
 2 8 (19.5) 3 (12.0) 21 (30.0)  
 3 12 (29.3) 5 (20.0) 16 (22.9)  
 4 13 (31.7) 7 (28.0) 13 (18.6)  
Previous therapy with PEG/RBV, n (%)       <0.001
 Treatment naïve 15 (36.6) 11 (50.0) 62 (92.5)  
 Relapser 16 (39.0) 2 (9.1) 2 (3.0)  
 Partial responder 6 (14.6) 3 (13.6) 2 (3.0)  
 Null responder 4 (9.8) 6 (27.3) 1 (1.5)  
Baseline ALT, U/L, mean (CI) 68.0 (41.0, 100.0) 71.0 (37.0, 99.0) 66.0 (42.0, 94.0) 0.96
Baseline AST, U/L, mean (CI) 54.0 (35.0, 79.0) 52.0 (41.0,87.0) 56.0 (41.5,99.5) 0.52
Baseline HCV RNA (×105), IU/mL, mean (CI) 24.0 (8.1, 64.6) 23.0 (9.4, 42.9) 8.0 (3.6, 15.4) <0.001
Baseline Serum Creatinine, mg/dL, mean (SD) 0.82 (0.20) 0.81(0.25) 0.92 (0.36) 0.25
Baseline Hemoglobin, g/dL, mean (SD) 14.8 (1.4) 14.9 (1.2) 14.9 (1.2) 0.93
Interferon dose, n, (%)       0.031
 peg-interferon alfa-2a 41(91.1)* 21(80.8) 48 (70.6)*  
 peg-interferon alfa-2b 4 (8.9) 5 (19.2) 20 (29.4)  
Values presented as Mean (Standard Deviation with Analysis of variance)
*Use of peg-interferon alfa-2a was significantly higher in Telaprevir arm as compared to PEG/RBV arm
Abbreviations: n=number of patients, CI=confidence interval, IVDU=Intravenous drug use, PEG=peg-interferon, RBV=ribavirin, ALT=alanine aminotransferase,
AST=aspartate aminotransferase, HCV=hepatitis C virus, U/L=units/Liter, IU/mL=International Units/milliliter, mg=milligram
Table 2: Baseline clinical and histologic data.
Goto home»